Response to Crizotinib in ROS1 Fusion-Positive Intrahepatic Cholangiocarcinoma
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
---|---|
Enthalten in: |
JCO precision oncology - 4(2020) vom: 10. Nov., Seite 825-828 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jakubowski, Christopher D [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 31.12.2022 published: Print Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1200/PO.20.00116 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM335854052 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM335854052 | ||
003 | DE-627 | ||
005 | 20231225230814.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1200/PO.20.00116 |2 doi | |
028 | 5 | 2 | |a pubmed24n1119.xml |
035 | |a (DE-627)NLM335854052 | ||
035 | |a (NLM)35050759 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Jakubowski, Christopher D |e verfasserin |4 aut | |
245 | 1 | 0 | |a Response to Crizotinib in ROS1 Fusion-Positive Intrahepatic Cholangiocarcinoma |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 31.12.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Mohan, Aditya A |e verfasserin |4 aut | |
700 | 1 | |a Kamel, Ihab R |e verfasserin |4 aut | |
700 | 1 | |a Yarchoan, Mark |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t JCO precision oncology |d 2017 |g 4(2020) vom: 10. Nov., Seite 825-828 |w (DE-627)NLM273576054 |x 2473-4284 |7 nnns |
773 | 1 | 8 | |g volume:4 |g year:2020 |g day:10 |g month:11 |g pages:825-828 |
856 | 4 | 0 | |u http://dx.doi.org/10.1200/PO.20.00116 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 4 |j 2020 |b 10 |c 11 |h 825-828 |